[
    [
        {
            "time": "2018-03-15",
            "original_text": "Emisphere Technologies, Inc. (OTC:EMIS) INVESTOR NOTICE: Abraham, Fruchter & Twersky, LLP Is Investigating the Sale of Emisphere and Encourages Investors to Contact the Firm",
            "features": {
                "keywords": [
                    "Investor Notice",
                    "Abraham, Fruchter & Twersky",
                    "Sale Investigation"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Emisphere Technologies, Inc. (OTC:EMIS) INVESTOR NOTICE: Abraham, Fruchter & Twersky, LLP Is Investigating the Sale of Emisphere and Encourages Investors to Contact the Firm",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-04-20",
            "original_text": "EMISPHERE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of EMIS and Encourages Investors to Contact the Firm",
            "features": {
                "keywords": [
                    "EMISPHERE ALERT",
                    "Bragar Eagel & Squire",
                    "Sale Investigation"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "EMISPHERE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of EMIS and Encourages Investors to Contact the Firm",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-05-10",
            "original_text": "Novo Nordisk A/S – Share repurchase programme",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Share Repurchase",
                    "Programme"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novo Nordisk A/S – Share repurchase programme",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-06-05",
            "original_text": "Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?",
            "features": {
                "keywords": [
                    "VanEck Vectors",
                    "Pharmaceutical ETF",
                    "Investment Question"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]